SCHEMBL5397356

SCHEMBL5397356

CN(Cc1cccc(-c2ccc(CC3SC(=O)NC3=O)cc2)c1)C(=O)CCCCCC(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.52
PPARG P37231 7/20 0.48
AOC3 Q16853 8/20 0.44
MPC2 O95563 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2C9 P11712 1/20 0.44
RARG P13631 1/20 0.41
RXRA P19793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5399129 0.99 FFAR1 (0.53) FFAR1PPARGAOC3MPC2CYP2C8
SCHEMBL5763775 0.91 FFAR1 (0.53) FFAR1PPARGAOC3RARGRXRA
SCHEMBL5762681 0.91 FFAR1 (0.53) FFAR1PPARGAOC3RARGRXRA
SCHEMBL6182509 0.89 FFAR1 (0.51) FFAR1AOC3
SCHEMBL6184372 0.89 FFAR1 (0.51) FFAR1AOC3
SCHEMBL6987927 0.89 FFAR1 (0.51) FFAR1AOC3
SCHEMBL6183069 0.89 FFAR1 (0.51) FFAR1AOC3
SCHEMBL6183217 0.89 FFAR1 (0.51) FFAR1AOC3
SCHEMBL6183077 0.88 FFAR1 (0.52) FFAR1AOC3
SCHEMBL5390713 0.88 FFAR1 (0.52) FFAR1PPARGAOC3MPC2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US claimed
US-7294639-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-11-13 US disclosed
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2007-02-22 US disclosed
US-7122564-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-17 US disclosed
EP-1458697-B1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RES & DEV (FR) 2006-09-06 EP disclosed
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. 2005-06-23 US disclosed
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US disclosed
EP-1458697-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS Galderma Research & Development, S.N.C. (FR) 2004-09-22 EP disclosed
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-07-17 US disclosed
WO-2003055867-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors PPARG, PPARA, PPARD FFAR1 13/4885PPARG 1/4885AOC3 2037/4885
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD FFAR1 13/4885PPARG 1/4885AOC3 2037/4885
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD FFAR1 10/4885PPARG 1/4885AOC3 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.